Efficacy of Lactobacillus Paracasei PS23 for Patients With Post-COVID-19 Syndrome
Reason given: The covid-19 epidemic was calming down and not many people were suffering from the post covid 19 syndrome
Key facts
- Where
- Taipei, TaiwanSee the site
Where in Taiwan
- MacKay Memorial HospitalTaipei, TaiwanNo longer taking part
Trial details
- Who runs it
- Mackay Memorial Hospital
- Trial code
- NCT05813899
- Record updated
- 15 August 2024
- Original description
To evaluate whether probiotics PS23 can improve the symptoms of patients with long COVID-19 ; also to evaluate the effects on blood cortisol and inflammation-related indicators in patients.Read full original descriptionShow less
To evaluate whether probiotics PS23 can improve the symptoms of patients with long COVID-19 ; also to evaluate the effects on blood cortisol and inflammation-related indicators in patients.
Inclusion: Aged above 20 years old and below 65 years old; Those who consciously have long COVID-19 symptoms or actively respond to website advertisements to express interest in participating in this clinical researcher; Those who received the confirmation SMS or the COVID-19 rapid test positive 4 weeks ago.
Exclusion: Have taken antibiotics within one month or are receiving antibiotic treatment; Prior to or currently taking medication for acute or psychiatric illness prior to the diagnosis of COVID-19; Cancer or immunocompromised patients undergoing treatment; Those who are allergic to lactic acid bacteria products; Diagnosed with dementia before being diagnosed with COVID-19; Have taken probiotic products have been used within two weeks (excluding yogurt, yogurt, Yakult and other related foods); The investigator judges that it is not suitable to participate in the researcher.